<DOC>
	<DOCNO>NCT02359032</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single multiple ascend oral dos ASP6858 . This study also evaluate pharmacokinetics ( PK ) ASP6858 metabolites well effect food PK ASP6858 . The study also evaluate pharmacodynamics ASP6858 .</brief_summary>
	<brief_title>A Combined Single Multiple Ascending Dose Study ASP6858 Healthy Subjects</brief_title>
	<detailed_description>This study 2 part : Part 1 placebo-controlled , single ascend dose study male subject residential 5-8 day ( Part 1 also include open-label , food effect section ) ; Part 2 placebo-controlled , randomize , 2-way crossover , multiple ascend dose study male female subject residential 14-17 day treatment period . There washout period 2 period Part 2 .</detailed_description>
	<criteria>Part 1 : Healthy male subject , 18 55 year age , inclusive , screen . Part 2 : Healthy male female subject , 18 55 year age , inclusive , screen . Subject body mass index range 18.5 30.0 kg/m2 , inclusive , weigh least 50 kg , screen . Subject stable eat habit weight ( Â± 2 kg ) last 4 week prior screen . Subject willing comply strictly diet apply clinical study . Subject agree participate another interventional study participate present clinical study , define signing informed consent form completion last study visit . Subject prior upper gastric , gastroduodenal , pancreatic small intestinal surgery . Subject lactose intolerance , gluten sensitivity condition significant nutritional malabsorption . Female subject pregnant within 6 month prior screen assessment breastfeed within 3 month prior screen . Subject know suspected hypersensitivity ASP6858 component formulation use . Subject liver chemistry test ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , alkaline phosphatase , gamma glutamyl transferase , total bilirubin [ TBL ] ) upper limit normal ( ULN ) . In case assessment may repeat day 1 ( part 2 : treatment period 1 ) . Subject clinically significant history allergic condition . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior admission clinical unit ( part 2 : treatment period 1 ) . Subject clinically significant abnormality follow investigator 's review physical examination , ECG protocoldefined clinical laboratory test screen admission clinical unit ( part 2 : treatment period 1 ) . Subject mean pulse &lt; 40 &gt; 90 bpm ; mean systolic blood pressure &gt; 140 mmHg ; mean diastolic blood pressure &gt; 90 mmHg ( vital sign measurement take triplicate subject rest supine position 5 minute ; pulse measure automatically ) screen day 1 ( part 2 : treatment period 1 ) . If blood pressure exceed limit , 1 additional triplicate take . Subject mean correct QT interval use Fridericia 's formula &gt; 430 m ( male subject ) &gt; 450 m ( female subject ) day 1 ( part 2 : treatment period 1 ) . If limit exceed , 1 additional triplicate ECG take . Subject use prescribe nonprescribed drug ( include vitamin , natural herbal remedy , e.g. , St. John 's Wort ) 2 week prior study drug administration , except occasional use paracetamol ( 2 g/day ) except use contraceptive hormone replacement therapy . Subject history smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission clinical unit ( part 2 : first admission ) . Subject history drink 21 unit ( male subject ) 14 unit ( female subject ) alcohol per week ( 1 unit = 10 g pure alcohol = 250 mL beer [ 5 % ] 35 mL spirit [ 35 % ] 100 mL wine [ 12 % ] ) within 3 month prior admission clinical unit ( part 2 : first admission ) . Subject use drug abuse within 3 month prior admission clinical unit ( part 2 : first admission ) . Subject use inducer metabolism ( e.g. , barbiturate , rifampin ) 1 month prior admission clinical unit ( part 2 : first admission ) . Subject significant blood loss , donate 1 unit ( 500 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior admission clinical unit ( part 2 : first admission ) . Subject positive serology test hepatitis B surface antigen , hepatitis A virus antibody ( immunoglobulin M ) , hepatitis C virus antibody antibodies human immunodeficiency virus type 1 ( HIV1 ) and/or type 2 ( HIV2 ) screening . Subject participate clinical study treat investigational drug within 3 month 5 terminal halflives , whichever longer , prior screen . Subject unable communicate , read understand English , condition , investigator 's opinion , make subject unsuitable clinical study participation . Subject employee Astellas Group , Clinical Research Organization vendor involve clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>Pharmacokinetics ASP6858</keyword>
	<keyword>ASP6858</keyword>
	<keyword>Pharmacodynamics ASP6858</keyword>
</DOC>